Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction reduces myocardial infarct size (the NACIAM trial [N-acetylcysteine in acute myocardial infarction])

Circulation

Volumn 136, Issue 10, 2017, Pages 894-903

  Pasupathy, Sivabaskari ^a,b,c   Tavella, Rosanna ^a,b,c   Grover, Suchi ^c,e   Raman, Betty ^a,b,c   Procter, Nathan E K ^a,b,c   Du, Yang Timothy ^a,c   Mahadavan, Gnanadevan ^a,c,d   Stafford, Irene ^b,c   Heresztyn, Tamila ^b,c   Holmes, Andrew ^b,c   Zeitz, Christopher ^a,b,c,d   Arstall, Margaret ^a,d   Selvanayagam, Joseph ^c,e,f   Horowitz, John D ^a,b,c   Beltrame, John F ^a,b,c,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Centre for Inflammatory Disease Research (CIDR)   (Australia)

^c Central Adelaide Local Health Network   (Australia)

^d Mental Health Services   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

^f SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Acetylcysteine; Myocardial infarction; Myocardial reperfusion injury; Nitroglycerin; Percutaneous coronary intervention; Televation myocardial infarction

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MALONALDEHYDE; MYELOPEROXIDASE; ORGANIC NITRATE; PLACEBO; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; SYNDECAN 1; TICAGRELOR; NITRIC ACID DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING DISORDER; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES; ST ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

ACETYLCYSTEINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRATES; PERCUTANEOUS CORONARY INTERVENTION; ST ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 85021815445     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.027575     Document Type: Article

References (46)

1. Stone GW, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM, Maehara A, Eitel I, Granger CB, Jenkins PL, Nichols M, Ben-Yehuda O. Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. J Am Coll Cardiol. 2016;67:1674-1683. doi: 10.1016/j.jacc.2016.01.069.
2. van Kranenburg M, Magro M, Thiele H, de Waha S, Eitel I, Cochet A, Cottin Y, Atar D, Buser P, Wu E, Lee D, Bodi V, Klug G, Metzler B, Delewi R, Bernhardt P, Rottbauer W, Boersma E, Zijlstra F, van Geuns RJ. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging. 2014;7:930-939. doi: 10.1016/j.jcmg.2014.05.010.
3. Christian TF, Schwartz RS, Gibbons RJ. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation. 1992;86:81-90.
4. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105:656-662.
5. Bethke A, Halvorsen S, Bøhmer E, Abdelnoor M, Arnesen H, Hoffmann P. Myocardial perfusion grade predicts final infarct size and left ventricular function in patients with ST-elevation myocardial infarction treated with a pharmaco-invasive strategy (thrombolysis and early angioplasty). EuroIntervention. 2015;11:518-524. doi: 10.4244/EIJY15M04-02.
6. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135. doi: 10.1056/NEJMra071667.
7. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007;12:217-234. doi: 10.1007/s10741-007-9026-1.
8. Heusch G. The coronary circulation as a target of cardioprotection. Circ Res. 2016;118:1643-1658. doi: 10.1161/CIRCRESAHA.116.308640.
9. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarct location. Circulation. 1988;78:906-919.
10. ISIS-4 A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction: ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669-685.
11. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343:1115-1122.
12. Sage PR, de la Lande IS, Stafford I, Bennett CL, Phillipov G, Stubberfield J, Horowitz JD. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation. 2000;102:2810-2815.
13. Chen Z, Foster MW, Zhang J, Mao L, Rockman HA, Kawamoto T, Kitagawa K, Nakayama KI, Hess DT, Stamler JS. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2005;102:12159-12164. doi: 10.1073/pnas.0503723102.
14. Sellke FW, Tomanek RJ, Harrison DG. L-cysteine selectively potentiates nitroglycerin-induced dilation of small coronary microvessels. J Pharmacol Exp Ther. 1991;258:365-369.
15. Horowitz JD, Antman EM, Lorell BH, Barry WH, Smith TW. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation. 1983;68:1247-1253.
16. Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest. 1985;76:703-708. doi: 10.1172/JCI112024.
17. Folts JD, Stamler J, Loscalzo J. Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries. Circulation. 1991;83:2122-2127.
18. Horowitz JD, Henry CA, Syrjanen ML, Louis WJ, Fish RD, Smith TW, Antman EM. Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris. Circulation. 1988;77:787-794.
19. Beltrame JF, Zeitz CJ, Unger SA, Brennan RJ, Hunt A, Moran JL, Horowitz JD. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. J Card Fail. 1998;4:271-279.
20. Arstall MA, Yang J, Stafford I, Betts WH, Horowitz JD. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction: safety and biochemical effects. Circulation. 1995;92:2855-2862.
21. Yesilbursa D, Serdar A, Senturk T, Serdar Z, Sag S, Cordan J. Effect of N-acetylcysteine on oxidative stress and ventricular function in patients with myocardial infarction. Heart Vessels. 2006;21:33-37. doi: 10.1007/s00380-005-0854-4.
22. Recio-Mayoral A, Chaparro M, Prado B, Cózar R, Méndez I, Banerjee D, Kaski JC, Cubero J, Cruz JM. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol. 2007;49:1283-1288. doi: 10.1016/j.jacc.2006.11.034.
23. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773-2782. doi: 10.1056/NEJMoa054209.
24. Bondarenko O, Beek AM, Hofman MB, Kühl HP, Twisk JW, van Dockum WG, Visser CA, van Rossum AC. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson. 2005;7:481-485.
25. Friedrich MG, Abdel-Aty H, Taylor A, Schulz-Menger J, Messroghli D, Dietz R. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1581-1587. doi: 10.1016/j.jacc.2008.01.019.
26. Lebeau R, Serri K, Morice MC, Hovasse T, Unterseeh T, Piéchaud JF, Garot J. Assessment of left ventricular ejection fraction using the wall motion score index in cardiac magnetic resonance imaging. Arch Cardiovasc Dis. 2012;105:91-98. doi: 10.1016/j.acvd.2012.01.002.
27. Wilkins ML, Maynard C, Annex BH, Clemmensen P, Elias WJ, Gibson RS, Lee KL, Pryor AD, Selker H, Turner J, Weaver WD, Anderson ST, Wagner GS. Admission prediction of expected final myocardial infarct size using weighted ST-segment, Q wave, and T wave measurements. J Electrocardiol. 1997;30:1-7.
28. Ingkanisorn WP, Rhoads KL, Aletras AH, Kellman P, Arai AE. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J Am Coll Cardiol. 2004;43:2253-2259. doi: 10.1016/j.jacc.2004.02.046.
29. Ibrahim T, Nekolla SG, Hörnke M, Bülow HP, Dirschinger J, Schömig A, Schwaiger M. Quantitative measurement of infarct size by contrastenhanced magnetic resonance imaging early after acute myocardial infarction: comparison with single-photon emission tomography using Tc99m-sestamibi. J Am Coll Cardiol. 2005;45:544-552. doi: 10.1016/j. jacc.2004.10.058.
30. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, Banning AP. Troponin elevation after percutaneous coronary inter vention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation. 2005;111:1027-1032. doi: 10.1161/01.CIR.0000156328.28485.AD.
31. Lønborg J, Vejlstrup N, Kelbak H, Bøtker HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Køber L, Treiman M, Holst JJ, Engstrøm T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491-1499. doi: 10.1093/eurheartj/ehr309.
32. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol. 2013;33:2252-2260. doi: 10.1161/ATVBAHA.113.301586.
33. Jones SP, Tang XL, Guo Y, Steenbergen C, Lefer DJ, Kukreja RC, Kong M, Li Q, Bhushan S, Zhu X, Du J, Nong Y, Stowers HL, Kondo K, Hunt GN, Goodchild TT, Orr A, Chang CC, Ockaili R, Salloum FN, Bolli R. The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ Res. 2015;116:572-586. doi: 10.1161/CIRCRESAHA. 116.305462.
34. Symons R, Masci PG, Francone M, Claus P, Barison A, Carbone I, Agati L, Galea N, Janssens S, Bogaert J. Impact of active smoking on myocardial infarction severity in reperfused ST-segment elevation myocardial infarction patients: the smoker's paradox revisited. Eur Heart J. 2016;37:2756-2764. doi: 10.1093/eurheartj/ehv738.
35. Winniford MD, Kennedy PL, Wells PJ, Hillis LD. Potentiation of nitroglycerin-induced coronary dilatation by N-acetylcysteine. Circulation. 1986;73:138-142.
36. May DC, Popma JJ, Black WH, Schaefer S, Lee HR, Levine BD, Hillis LD. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med. 1987;317:805-809. doi: 10.1056/NEJM198709243171305.
37. Chirkov YY, Horowitz JD. N-acetylcysteine potentiates nitroglycerininduced reversal of platelet aggregation. J Cardiovasc Pharmacol. 1996;28:375-380.
38. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799-804. doi: 10.1056/NEJM198709243171304.
39. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol. 2001;33:1897-1918. doi: 10.1006/jmcc.2001.1462.
40. Heusch G, Rassaf T. Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning. Circ Res. 2016;119:676-695. doi: 10.1161/CIRCRESAHA.116.308736.
41. Cung TT, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D, Bonnefoy-Cudraz E, Guérin P, Elbaz M, Delarche N, Coste P, Vanzetto G, Metge M, Aupetit JF, Jouve B, Motreff P, Tron C, Labeque JN, Steg PG, Cottin Y, Range G, Clerc J, Claeys MJ, Coussement P, Prunier F, Moulin F, Roth O, Belle L, Dubois P, Barragan P, Gilard M, Piot C, Colin P, De Poli F, Morice MC, Ider O, Dubois-Randé JL, Unterseeh T, Le Breton H, Béard T, Blanchard D, Grollier G, Malquarti V, Staat P, Sudre A, Elmer E, Hansson MJ, Bergerot C, Boussaha I, Jossan C, Derumeaux G, Mewton N, Ovize M. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015;373:1021-1031. doi: 10.1056/NEJMoa1505489.
42. Mewton N, Croisille P, Gahide G, Rioufol G, Bonnefoy E, Sanchez I, Cung TT, Sportouch C, Angoulvant D, Finet G, André-Fouët X, Derumeaux G, Piot C, Vernhet H, Revel D, Ovize M. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol. 2010;55:1200-1205. doi: 10.1016/j.jacc.2009.10.052.
43. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473-481. doi: 10.1056/NEJMoa071142.
44. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol. 2010;55:2201-2209. doi: 10.1016/j.jacc.2009.08.091.
45. Bridgeman MM, Marsden M, MacNee W, Flenley DC, Ryle AP. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax. 1991;46:39-42.
46. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol. 1988;34:77-82.